Search clinical trials for: AZD9592

Total 127 results

AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK)

Breast Cancer

United States
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study (SAD)

Healthy Volunteer

United States
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Completed

AZD8529 Multiple Ascending Dose Study in Healthy Subjects

Healthy Volunteer
AstraZeneca

Completed

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Healthy | Memory Impairment

United States
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
National Institute on Drug Abuse (NIDA)

Completed

The Study of AZD8529 for Smoking Cessation in Female Smokers

Tobacco Use Disorder

United States
AstraZeneca

Completed

AZD9496 First Time in Patients Ascending Dose Study

ER+ HER2- Advanced Breast Cancer

United States, United Kingdom, Korea, Republic of
AstraZeneca
Parexel

Completed

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Asthma

Germany
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Asthma

United States
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Japan, Sweden
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Non-alcoholic Steatohepatitis

United Kingdom
AstraZeneca

Completed

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Oncology

United Kingdom
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
AstraZeneca
TigerMed

Completed

T790M Plasma Testing Methodology Comparison and Clinical Validation (ADELOS)

Lung Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
Shaare Zedek Medical Center
AstraZeneca

Recruiting

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Lung Cancer, Non-small Cell

Israel
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Chonnam National University Hospital

Completed

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA (LiquidLung-O)

Lung Neoplasms | EGFR Gene Mutations

Korea, Republic of
AstraZeneca

Terminated

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC (MINOVA)

Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Oslo University Hospital
AstraZeneca

Active, not recruiting

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies (TREM)

Lung Cancer | Targeted Therapy

Sweden, Finland, Denmark, Lithuania, Norway
Soroka University Medical Center

Active, not recruiting

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Lung Cancer

Israel
MedSIR
AstraZeneca

Completed

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (AZENT)

Non-Small Cell Lung Cancer

Spain
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
AstraZeneca
Parexel

Active, not recruiting

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)

Non-small Cell Lung Cancer

Italy, Spain, United States, China, Germany, Israel

3

Subscribe